Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells

Cell Cycle

Volumn 11, Issue 12, 2012, Pages 2314-2326

  Pan, Jingxuan ^a   Chen, Chun ^b   Jin, Yanli ^a   Fuentes Mattei, Enrique ^c   Velazquez Tores, Guermarie ^c   Benito, Juliana Maria ^c   Konopleva, Marina ^c   Andreeff, Michael ^c   Lee, Mong Hong ^c   Yeung, Sai Ching Jim ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Chemoresistance; Insulin; Metformin; Secretagogues; Thiazolidinediones

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; ETOPOSIDE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN KINASE B; ROSIGLITAZONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIVITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SIGNAL TRANSDUCTION;

EID: 84862891813     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20770     Document Type: Article

References (63)

1. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001; 84:417-22; PMID:11161410; http://dx.doi.org/10.1054/bjoc.2000.1582.
2. Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 2003; 26:1047- 51; PMID:12663571; http://dx.doi.org/10.2337/diacare.26.4.1047.
3. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2:48-53; PMID:16264856; http://dx.doi.org/10.1038/ncponc0062.
4. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159:1160-7; PMID:15191933; http://dx.doi.org/10.1093/aje/kwh161.
5. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 2007; 120:1986-92; PMID:17230509; http://dx.doi.org/10.1002/ijc.22532.
6. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547-61;PMID:10653870.
7. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone/methotrexate- cytarabine regimen. Cancer 2004; 100:1179- 85; PMID:15022284; http://dx.doi.org/10.1002/cncr.20071.
8. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose and risk of cause-specific death. N Engl J Med 2011; 364:829-41; PMID:21366474; http://dx.doi.org/10.1056/NEJMoa1008862.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013.
10. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14; PMID:13298683; http://dx.doi.org/10.1126/science.123.3191.309.
11. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci 2008; 65:3981-99; PMID:18766298; http://dx.doi.org/10.1007/s00018-008-8224-x.
12. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 2011; 15:825-36; PMID:20455996; http://dx.doi.org/10.1111/j.1582-4934. 2010.01083.x.
13. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674- 85; PMID:20587728; http://dx.doi.org/10.2337/dc10-0666.
14. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NFkappaB pathway and generation of reactive oxygen species. Cancer Res 2010; 70:2516-27; PMID:20215516; http://dx.doi.org/10.1158/0008-5472.CAN-09-3950.
15. Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007; 109:315-22; PMID:16912224; http://dx.doi.org/10.1182/blood-2006-04-013805.
16. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15:1686-97; PMID:19240172; http://dx.doi.org/10.1158/1078-0432.CCR-08-2141.
17. Malone JI, Lowitt S, Grove NP, Shah SC. Comparison of insulin levels after injection by jet stream and disposable insulin syringe. Diabetes Care 1986; 9:637- 40; PMID:3542456; http://dx.doi.org/10.2337/diacare.9.6.637.
18. van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011; 36:376- 82; PMID:21545617; http://dx.doi.org/10.1111/ j.1365-2710.2010.01192.x.
19. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003; 46:1319-23; PMID:12898007; http://dx.doi.org/10.1007/s00125- 003-1181-x.
20. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-12; PMID:18006825; http://dx.doi.org/10.1158/0008-5472.CAN-07-2310.
21. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012; 26:91-100; PMID:21968881; http://dx.doi.org/10.1038/leu.2011.269.
22. Farrow B, Evers BM. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003; 301:50-3; PMID:12535639; http://dx.doi.org/10.1016/S0006-291X(02)02983-2.
23. Boren J, Cascante M, Marin S, Comín-Anduix B, Centelles JJ, Lim S, et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 2001; 276:37747-53;PMID:11489902.
24. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 1974; 23:9-15; PMID:4809622.
25. Gapstur SM, Gann PH, Colangelo LA, Barron- Simpson R, Kopp P, Dyer A, et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 2001; 12:763-72; PMID:11562117; http://dx.doi.org/10.1023/A:1011279907108.
26. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20:42-51; PMID:11773152; http://dx.doi.org/10.1200/JCO.20.1.42.
27. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, 3rd, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003; 21:433-40; PMID:12560431; http://dx.doi.org/10.1200/ JCO.2003.07.125.
28. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 2011; 15:825-36; PMID:20477906; http://dx.doi.org/10.1111/j.1582-4934. 2010.01083.x.
29. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52:1732-44; PMID:19565214; http://dx.doi.org/10.1007/s00125-009-1418-4.
30. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52:1755-65; PMID:19603149; http://dx.doi.org/10.1007/s00125-009-1453-1.
31. Currie CJ, Poole CD, Gale EA. The influence of glucose- lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52:1766-77; PMID:19572116; http://dx.doi.org/10.1007/s00125-009-1440-6.
32. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52:2499-506; PMID:19756478; http://dx.doi.org/10.1007/s00125-009-1530-5.
33. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population- based follow-up study in Sweden. Diabetologia 2009; 52:1745-54; PMID:19588120; http://dx.doi.org/10.1007/s00125-009-1444-2.
34. Wilson C. Diabetes: long-term use of insulin glargine might increase the risk of breast cancer. Nat Rev Endocrinol 2011; 7:499; PMID:21709708; http://dx.doi.org/10.1038/nrendo.2011.112.
35. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008; 114:38-44; PMID:18465357; http://dx.doi.org/10.1080/13813450801900645.
36. Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 2010; 116:73-8; PMID:20199195; http://dx.doi.org/10.3109/13813451003631439.
37. Liefvendahl E, Arnqvist HJ. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 2008; 40:369-74; PMID:18393172; http://dx.doi.org/10.1055/s-2008-1062739.
38. Erbel S, Reers C, Eckstein VW, Kleeff J, Büchler MW, Nawroth PP, et al. Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 2008; 31:1105-11; PMID:18316392; http://dx.doi.org/10.2337/dc07-2015.
39. Müller K, Weidinger C, Führer D. Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol-3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells. Diabetologia 2010; 53:1001-3; PMID:20179899; http://dx.doi.org/10.1007/s00125- 010-1674-3.
40. Nagel JM, Staffa J, Renner-Müller I, Horst D, Vogeser M, Langkamp M, et al. Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Horm Cancer 2010; 1:320-30; PMID:21761363; http://dx.doi.org/10.1007/ s12672-010-0020-z.
41. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras- Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896-917; PMID:22203527.
42. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67:6745-52; PMID:17638885; http://dx.doi.org/10.1158/0008-5472.CAN-06-4447.
43. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007; 64:1290-302; PMID:17447005; http://dx.doi.org/10.1007/s00018-007-7080-4.
44. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008; 14:7192- 8; PMID:19084933; http://dx.doi.org/10.3748/wjg.14.7192.
45. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9:1091- 6; PMID:20190568; http://dx.doi.org/10.4161/ cc.9.6.11035.
46. Fenner MH, Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 2005; 14:557-68; PMID:16004588; http://dx.doi.org/10.1517/13543784.14.6.557.
47. Lyles BE, Akinyeke TO, Moss PE, Stewart LV. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 2009; 8:268-77; PMID:19164938; http://dx.doi.org/10.4161/cc.8.2.7584.
48. Dong YW, Wang XP, Wu K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator- activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol 2009; 15:441-8; PMID:19152448; http://dx.doi.org/10.3748/wjg.15.441.
49. Papageorgiou E, Pitulis N, Manoussakis M, Lembessis P, Koutsilieris M. Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med 2008; 14:403-11; PMID:18475308; http://dx.doi.org/10.2119/2008-00021.Papageorgiou.
50. Cantini G, Lombardi A, Piscitelli E, Poli G, Ceni E, Marchiani S, et al. Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res 2008; 2008:904041; PMID:18670617; http://dx.doi.org/10.1155/2008/904041.
51. Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer 2006; 118:2390-8; PMID:16425225; http://dx.doi.org/10.1002/ijc.21799.
52. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2:760-74; PMID:21084729.
53. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010; 9:1781- 91; PMID:20436278; http://dx.doi.org/10.4161/cc.9.9.11483.
54. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7:455-65; PMID:20531380; http://dx.doi.org/10.1038/nrclinonc.2010.82.
55. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2011; PMID:22112968; http://dx.doi.org/10.1093/annonc/mdr534.
56. He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011; 22:2640-5; PMID:21415239; http://dx.doi.org/10.1093/annonc/mdr020.
57. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18:2905-12; PMID:22465831; http://dx.doi.org/10.1158/1078- 0432.CCR-11-2994.
58. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29:254-8; PMID:16443869; http://dx.doi.org/10.2337/diacare. 29.02.06.dc05-1558.
59. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297-302; PMID:19487376; http://dx.doi.org/10.1200/JCO.2009.19.6410.
60. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, et al. A randomized controlled trial of an intensive insulin regimen in hyperglycemic acute lymphoblastic leukemia patients. Clin Lymphoma Myeloma Leuk 2012; In press.
61. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011; 126:215-20; PMID:20976543; http://dx.doi.org/10.1007/s10549-010- 1224-1.
62. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222-33; PMID:21447859.
63. Jin Y, Chen Q, Shi X, Lu Z, Cheng C, Lai Y, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci 2009; 100:1335-43; PMID:19383029; http://dx.doi.org/10.1111/j.1349-7006.2009. 01159.x.